Rein Therapeutics receives third $1.0M Pre-Paid Advance from Yorkville at 95% discount

Rein Therapeutics, Inc.

Third Pre-Paid Advance of $1.0M on Oct 23, 2025; net proceeds $0.95M; total potential up to $6.0M.
Interest accrues at 8% annually (18% on default); advances due 12 months from issuance.
Yorkville may demand common stock issuance to offset outstanding balance; prior advances converted at avg prices ~$1.0562 and ~$1.0825 per share.
First and Second Advances of $1.0M each previously drawn; combined shares issued: ~1.88M.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Rein Therapeutics, Inc. incurred debt of $1.0 million with YA II PN, Ltd. at 8% maturing 12-month anniversary of their issuance.

Principal: $1.0 million
Counterparty: YA II PN, Ltd.
Rate: 8%
Maturity: 12-month anniversary of their issuance
Event: incurrence

Exact text from the filing

(the “Company”, “we”, “us”) in a Current Report on Form 8-K filed on July 30, 2025, on July 29, 2025 (the “Effective Date”), we entered into a Pre-Paid Advance Agreement (the “PPA”) with YA II PN, Ltd., a Cayman Islands exempt limited partnership (“Yorkville”). In accordance with the terms of the PPA, we may request pre-paid advances of up to $6.0 million from Yorkville (each, a “Pre-Paid Advance”) over a 12-month period, subject to certain limitations and conditions set forth in the PPA.

View on SEC.gov

306 debt financings filed in the last 30 days. Browse all debt financings →

Rein Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-250175

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.